Aethlon Medical, Inc. (Nasdaq: AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, announced today (Monday, November16, 2015) its results for the second quarter of fiscal 2016 ended September 30, 2015. "Beyond achieving the short-term objectives set forth in our last quarterly call, we also made material advancements that should benefit our long-term clinical and commercialization endeavors," stated Jim Joyce, Chairman and CEO of Aethlon Medical. "We transitioned to a new Principal Investigator to support our clinical study in Houston, we secured year-5 approval of our primary DARPA contract, kicked-off a cancer-related study at UC-Irvine Medical Center, launched two new virus study collaborations, and our Exosome Sciences subsidiary submitted a manuscript for publication with our CTE (chronic traumatic encephalopathy) study collaborators. We also made manufacturing-related advances and introduced a partnering program to establish new Aethlon ADAPT™-based therapies that target disease indications not addressed by our Hemopurifier®." [BioQuick Editor’s Note: An interesting side-story here is the Aethlon CEO Jim Joyce once played NFL football with the Denver Broncos.] Aethlon Medical creates affinity biofiltration devices to treat life-threatening diseases. OThe company’s lead therapeutic candidate is the Aethlon Hemopurifier®, a first-in-class device that targets the rapid elimination of infectious viruses and cancer-promoting exosomes from the circulatory system of treated individuals. U.S. clinical progression of Hemopurifier therapy is being advanced under an FDA-approved clinical study. The company also provides government contracting services to the Defense Advanced Research Projects Agency related to the development of a biofiltration device to treat sepsis.
Login Or Register To Read Full Story